 |
Dr. Wang, Kai-Hung | |
| E-mail:Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它 | ||
| Ext：15614 | ||
| Tzu Chi University, Taiwan. Ph.D. | ||
|
Expertise： Molecular biology and immuno-oncology.
|
Experence：
Institute of Biotechnology and Pharmaceutical Research, NHRI. Postdoctoral fellow
Interest：
Tumor biology
Immuno-oncology
Cell therapy
Publication (in five years)：：
|
1. |
Wang K-H, Ding D-C (2021) Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment. Tzu Chi Med J 33: 250–256. |
|
2. |
Dongoran RA, Wang K-H, Lin T-J, Yuan T-C, Liu C-H (2020) Anti-Proliferative Effect of Statins Is Mediated by DNMT1 Inhibition and p21 Expression in OSCC Cells. Cancers 12: doi:10.3390/cancers12082084. |
| 3. | Wang K-H, Chu S-C, Chu T-Y (2017) Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium. Oncotarget 8: 61133–61145. |
| 4. | Wang K-H, Lin C-J, Liu C-J, Liu D-W, Huang R-L, Ding D-C, Weng C-F, Chu T-Y (2015) Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV. Cancer Med 4: 43–55. |
